About 111, Inc.
https://www.111.com.cn111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C.
CEO
Junling Liu
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Medical - Pharmaceuticals
Sector Healthcare
Went public September 12, 2018
Method of going public IPO
Full time employees 1,238
Ratings Snapshot
Rating : C+
Discounted Cash Flow 5
Return On Equity 3
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
ELEPHAS INVESTMENT MANAGEMENT LTD
Shares:1.44M
Value:$8.31M
GREENWOODS ASSET MANAGEMENT LTD
Shares:501.85K
Value:$2.89M
RUDMAN ERROL M
Shares:191.71K
Value:$1.1M
Summary
% Of Shares Owned 24.64%
Total Number Of Holders 3
Showing Top 3 of 3
Market Cap $24.70 M
52w High $11.35
52w Low $0.42
P/E -2.05
Volume 15.17K
Outstanding Shares 8.67M
About 111, Inc.
https://www.111.com.cn111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $419.26M ▼ | $180.33M ▲ | $-1.81M ▲ | -0.43% ▲ | $-0.2 ▲ | $782.26K ▼ |
| Q2-2025 | $3.21B ▼ | $95.08M ▼ | $-19.55M ▼ | -0.61% ▼ | $-2.24 ▼ | $4.34M ▲ |
| Q1-2025 | $3.53B ▼ | $194.95M ▼ | $-17.65M ▲ | -0.5% ▲ | $-2.04 ▲ | $1.44M ▲ |
| Q4-2024 | $3.85B ▲ | $209.8M ▲ | $-19.84M ▼ | -0.52% ▼ | $-2.3 ▼ | $-3.04M ▼ |
| Q3-2024 | $3.6B | $208.25M | $-17.11M | -0.48% | $-1.98 | $7.82M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $493.62M ▲ | $2.48B ▲ | $2.26B ▲ | $-683.89M ▼ |
| Q2-2025 | $447.47M ▼ | $2.48B ▼ | $2.15B ▼ | $-673.07M ▼ |
| Q1-2025 | $485.74M ▲ | $2.61B ▼ | $2.23B ▼ | $-656.26M ▼ |
| Q4-2024 | $462.29M ▼ | $2.79B ▼ | $2.41B ▼ | $-642.64M ▼ |
| Q3-2024 | $581.98M | $3.03B | $2.72B | $-629.58M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-19.55M ▼ | $-61.41M ▼ | $-223K ▲ | $18.67M ▲ | $-43.73M ▼ | $-61.41M ▼ |
| Q1-2025 | $-17.65M ▲ | $112.6M ▲ | $-1.09M ▼ | $-72.98M ▼ | $38.5M ▲ | $112.6M ▲ |
| Q4-2024 | $-20.78M ▼ | $-48.55M ▼ | $37.52M ▼ | $-35.78M ▲ | $-46.08M ▼ | $-63.75M ▼ |
| Q3-2024 | $0 ▲ | $109.86M ▲ | $49.84M ▲ | $-110.51M ▼ | $48.89M ▲ | $109.86M ▲ |
| Q2-2024 | $-14.02M | $93.26M | $-79.73M | $-104.47M | $-91.81M | $93.26M |
CEO
Junling Liu
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Medical - Pharmaceuticals
Sector Healthcare
Went public September 12, 2018
Method of going public IPO
Full time employees 1,238
Ratings Snapshot
Rating : C+
Discounted Cash Flow 5
Return On Equity 3
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
ELEPHAS INVESTMENT MANAGEMENT LTD
Shares:1.44M
Value:$8.31M
GREENWOODS ASSET MANAGEMENT LTD
Shares:501.85K
Value:$2.89M
RUDMAN ERROL M
Shares:191.71K
Value:$1.1M
Summary
% Of Shares Owned 24.64%
Total Number Of Holders 3
Showing Top 3 of 3